Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The board of Bansisons Tea Industries Ltd met on November 19, 2025 and approved several major changes, all subject to shareholder approval via postal ballot. First, the company plans to rename itself from 'Bansisons Tea Industries Limited' to either 'Quantum Care Pharmachem Limited' or 'Novyra Pharmachem Limited', signalling a likely shift from tea to pharmaceutical business. Second, the board approved changing the Object Clause of its Memorandum of Association, again pointing to a business pivot. Third, it approved the sale of company land under Section 180(1)(a) of the Companies Act, 2013. Separately, Independent Director Mrs. Mamy Ghosh (DIN: 06532484) resigned effective November 19, 2025, citing pre-occupation. The board also appointed a scrutinizer for the postal ballot process.
This is a significant transformation announcement — the name change and object clause revision strongly suggest the company is pivoting away from tea into the pharmaceutical sector, which could change its risk profile and investor appeal. Shareholders will need to vote on the postal ballot, and the land sale could unlock capital. However, the resignation of an independent director and the small-cap nature of the stock mean investors should watch for details on the new business direction before taking positions.